Withdrawn 2.0-update on withdrawn drugs with pharmacovigilance data

Area of Science:

• Pharmacovigilance and Drug Development
• Computational Drug Discovery
• Medicinal Chemistry

Background:

• Drug development faces challenges with off-target interactions causing side effects and withdrawals.
• Off-target interactions can present opportunities for drug repositioning to new indications.
• Existing data on withdrawn drugs are fragmented across multiple national sources.

Purpose of the Study:

• To update and expand the Withdrawn database with comprehensive pharmacovigilance and drug-target information.
• To facilitate insights into drug withdrawals and potential drug repositioning strategies.
• To improve the accessibility and usability of withdrawn drug data.

Main Methods:

• Integrated FDA Adverse Event Reporting System (FAERS) pharmacovigilance data.
• Added mechanism of action and human disease pathway prediction features.
• Continuously updated lists of withdrawn drugs and their associated targets.
• Implemented systematic browsing options like an Anatomical Therapeutic Chemical (ATC) tree.

Main Results:

• The Withdrawn database (version 2.0) now includes extensive pharmacovigilance data and predictive features.
• Enhanced data accessibility through user-friendly browsing and updated drug lists.
• The updated database supports research into drug withdrawals and repositioning.

Conclusions:

• The enhanced Withdrawn 2.0 database provides a valuable, publicly accessible resource for drug repurposing and safety research.
• Improved data integration and accessibility streamline the investigation of drug withdrawals and off-target effects.
• This resource supports the identification of new therapeutic opportunities for previously withdrawn medications.